Literature DB >> 23355077

The characterisation and determinants of quality of life in ANCA associated vasculitis.

Neil Basu1, Andrew McClean, Lorraine Harper, Esther Nicole Amft, Neeraj Dhaun, Raashid A Luqmani, Mark A Little, David Rw Jayne, Oliver Flossmann, John McLaren, Vinod Kumar, Lars P Erwig, David M Reid, Gareth T Jones, Gary J Macfarlane.   

Abstract

OBJECTIVES: To contextualise and identify the determinants of poor health related quality of life (QOL) among patients with antineutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV).
METHODS: A multicentre AAV case-control study was conducted using two matched groups of population and chronic disease controls. Measures of physical and mental QOL as well as putative bio-psychosocial determinants of QOL impairment were collected. Concurrently, putative clinical QOL determinants were recorded. Conditional logistic regression analyses characterised group differences while multivariable logistic regression identified within-case QOL associations which were further quantified using population attributable risks (PAR).
RESULTS: Cases (n=410) experienced similar QOL to chronic disease controls (n=318) (physical QOL: OR 0.7, 95% CI 0.4 to 1.1; mental QOL: OR 1.1, 95% CI 0.8 to 1.6). However, they were substantially more likely to report poor QOL compared to general population controls (n=470) (physical QOL: OR 7.0, 95% CI 4.4 to 11.1; mental QOL: OR 2.5, 95% CI 1.7 to 3.6). A few clinical, but many more bio-psychosocial factors were independently associated with poor QOL. In population terms, fatigue was found to be of principal importance (physical QOL: PAR 24.6%; mental QOL: PAR 47.4%).
CONCLUSIONS: AAV patients experienced significant QOL impairment compared to the general population, but similar to those with other chronic diseases whose considerable needs are already recognised. Potentially modifiable clinical determinants have been identified; however bio-psychosocial interventions are likely to provide the greater QOL gains in this patient population.

Entities:  

Keywords:  Granulomatosis with Polyangiitis; Outcomes Research; Systemic Vasculitis

Mesh:

Substances:

Year:  2013        PMID: 23355077     DOI: 10.1136/annrheumdis-2012-202750

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

Review 1.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

2.  Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis.

Authors:  Karen E James; Rui Xiao; Peter A Merkel; Pamela F Weiss
Journal:  Clin Exp Rheumatol       Date:  2016-10-06       Impact factor: 4.473

Review 3.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

4.  OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Authors:  Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

5.  Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González; Natasha Alcocer-Castillejos
Journal:  Rheumatol Int       Date:  2017-12-15       Impact factor: 2.631

6.  Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.

Authors:  Rennie L Rhee; Susan L Hogan; Caroline J Poulton; Julie Anne G McGregor; J Richard Landis; Ronald J Falk; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

7.  Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.

Authors:  Joanna C Robson; Jill Dawson; Helen Doll; Peter F Cronholm; Nataliya Milman; Katherine Kellom; Susan Ashdown; Ebony Easley; Don Gebhart; Georgia Lanier; John Mills; Jacqueline Peck; Raashid Ahmed Luqmani; Judy Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2018-04-25       Impact factor: 19.103

8.  The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire.

Authors:  Janice Mooney; Nicola Spalding; Fiona Poland; Peter Grayson; Renee Leduc; Carol A McAlear; Rachel L Richesson; Denise Shereff; Peter A Merkel; Richard A Watts
Journal:  Rheumatology (Oxford)       Date:  2014-03-12       Impact factor: 7.580

9.  Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study.

Authors:  Matthew A Rutherford; Jennifer Scott; Maira Karabayas; Marilina Antonelou; Seerapani Gopaluni; David Gray; Joe Barrett; Silke R Brix; Neeraj Dhaun; Stephen P McAdoo; Rona M Smith; Colin C Geddes; David Jayne; Raashid Luqmani; Alan D Salama; Mark A Little; Neil Basu
Journal:  Arthritis Rheumatol       Date:  2021-07-27       Impact factor: 15.483

10.  Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study.

Authors:  Liqin Wang; Eli Miloslavsky; John H Stone; Hyon K Choi; Li Zhou; Zachary S Wallace
Journal:  Semin Arthritis Rheum       Date:  2020-12-24       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.